类风湿关节炎患者甲氨蝶呤治疗结局的临床预测模型:系统综述与Meta分析
该系统综述与Meta分析纳入13项开发研究和4项验证研究,共识别20个预测甲氨蝶呤治疗结局的临床预测模型,结局类型包括疾病活动状态、EULAR反应标准和因不良事件停药。总体偏倚风险高,仅9个模型进行内部验证,两个经多次外部验证的模型c-statistic分别为0.77(95%CI:0.69,0.84)和0.68(0.64,0.71)。
要点
- 共识别20个预测甲氨蝶呤治疗结局的模型,结局以疾病活动状态为主(n=14,70%)。
- 仅9个(45%)模型进行内部验证,总体偏倚风险高。
- 两个经多次外部验证的模型c-statistic为0.77(95%CI:0.69,0.84)和0.68(0.64,0.71)。
核心结论
- 本综述揭示了若干方法学缺陷,未来模型开发应加以解决以提高实践转化潜力。
研究设计与样本
- 系统综述与Meta分析,检索Medline和Embase,纳入开发或验证类风湿关节炎患者甲氨蝶呤治疗结局预测模型的研究。
- 共识别13项研究中的20个临床预测模型及4项验证研究。
- 使用PROBAST评估偏倚风险,对具有多次外部验证的模型采用固定效应Meta分析汇总区分度。
主要发现
- 结局类型包括疾病活动状态(n=14,70%)、EULAR反应标准(n=4,20%)和因不良事件停药(n=2,10%)。
- 仅1个模型考虑了潜在竞争风险,9个(45%)模型进行内部验证。
- 8个(40%)模型使用多重插补处理缺失数据,其他模型常限于完整病例分析。
- 总体偏倚风险高。
- 两个经多次外部验证的模型c-statistic分别为0.77(95%CI:0.69,0.84)和0.68(0.64,0.71)。
关键数值与推荐
- 两个经多次外部验证的模型c-statistic分别为0.77(95%CI:0.69,0.84)和0.68(0.64,0.71)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 总体偏倚风险高。
- 仅1个模型考虑了潜在竞争风险。
- 仅9个(45%)模型进行内部验证。
- 8个(40%)模型使用多重插补处理缺失数据,其他模型常限于完整病例分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the management of rheumatoid arthritis (RA), there is a clinical need to identify which patients are at high-risk of not responding to methotrexate (MTX), or experiencing adverse events (AEs), to enable earlier alternative treatments. Many clinical prediction models (CPMs) have previously been developed, but a summary of such models and their methodological quality is lacking. This systematic review aimed to (i) identify and summarize previously published CPMs of MTX outcomes in biologic-naïve RA patients, and (ii) critically appraise their methodological properties. METHODS: Medline and Embase were searched to identify studies developing or validating CPMs of MTX outcomes in RA patients. The risk of bias (ROB) was assessed using PROBAST (prediction model risk of bias assessment tool). A fixed effects meta-analysis summarised discrimination for models with multiple external validations. RESULTS: The systematic review identified 20 CPMs across 13 studies, and 4 validation studies. Three outcome types were used: a state of disease activity (n = 14, 70%); EULAR response criteria (n = 4, 20%); or discontinuation due to AEs (n = 2, 10%). Only one model accounted for potential competing risks, and nine (45%) were internally validated. Eight (40%) models used multiple imputation for missing data, others were often limited to complete case analysis. There was overall high ROB. The meta-analysis summarised c-statistics for two models with multiple external validations was 0.77 (95% CI: 0.69, 0.84) and 0.68 (0.64, 0.71). CONCLUSION: This review highlights several methodological shortcomings that should be addressed in future model development to increase potential for implementation into practice.
引用
- Gehringer CK, Martin GP, Hyrich KL, et al. Clinical prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2022. PMID: 35921745. doi:10.1016/j.semarthrit.2022.152076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。